National Health Commission and National Administration of Traditional Chinese Medicine: Azvudine Included in the Diagnosis and Treatment Guideline for COVID-19

On Aug. 9, 2022, National Health Commission and National Administration of Traditional Chinese Medicine announced that Azvudine has been included in the Diagnosis and Treatment Guideline for COVID-19.

Notice on the Inclusion of Azvudine in the Diagnosis and Treatment Guideline for COVID-19

To all provinces, autonomous regions, direct-administered municipalities, the Health Commission of Xinjiang Production and Construction Corps, and National Administration of Traditional Chinese Medicine:

According to the approval opinions from the National Medical Products Administration on the conditional approval of azvudine tablets for indication expansion to the treatment of COVID-19, the drug is included in the "Diagnosis and Treatment Guideline for COVID-19 (Version 9)" after discussions to further improve the anti-COVID-19 treatment protocol.Details are as below:

1. Drug Name

Azvudine tablets.

2. Indication

Treatment of common coronavirus disease 2019 (COVID-19) in adults.

3. Dosage and Administration

Swallow the whole tablet on an empty stomach, 5 mg each time, once a day, for a maximum treatment course of 14 days.

4. Precautions

It is not recommended for use during pregnancy and lactation. Use with caution in patients with moderate to severe hepatic or renal impairment.

Before using the drug, read the "Instructions for Azvudine Tablets" approved by the National Medical Products Administration in detail and properly apply the drug according to the indications, dosage and administration specified in the instructions.Patients should administer the drug under the guidance of a physician.Physicians should be familiar with contraindications, adverse reactions, and drug-drug interactions before prescribing the drug, and ask patients in detail about their drug allergy history and other conditions to avoid the use in patients with contraindications.All regions should monitor and report the adverse reactions in strict accordance with the requirements of "Measures for the Reporting and Monitoring of Adverse Drug Reactions" to ensure the safety of drug use.

Office of National Health Commission

Office of National Administration of Traditional Chinese Medicine

Aug. 9, 2022